H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.
StudyFinds on MSN19h
Journavx: What to know about new FDA-approved non-opioid pain medicationIntroducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback